These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 14840316)

  • 1. [Re-synthesis of biologically active insulin].
    BRESLER SE; GLIKINA MV; TONGUR AM
    Dokl Akad Nauk SSSR; 1951 May; 78(3):543-5. PubMed ID: 14840316
    [No Abstract]   [Full Text] [Related]  

  • 2. Protein kinase C activation increases transepithelial transport of biologically active insulin.
    Mullin JM; Ginanni N; Laughlin KV
    Cancer Res; 1998 Apr; 58(8):1641-5. PubMed ID: 9563475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of relaxin-2 and insulin-like peptide 5 enabled by novel tethering and traceless chemical excision.
    Thalluri K; Kou B; Yang X; Zaykov AN; Mayer JP; Gelfanov VM; Liu F; DiMarchi RD
    J Pept Sci; 2017 Jun; 23(6):455-465. PubMed ID: 28466571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oxalate on the re-initiation of DNA synthesis in LLC-PK1 cells do not involve p42/44 MAP kinase activation.
    Koul S; Chaturvedi LS; Sekhon A; Bhandari A; Menon M; Koul HK
    Kidney Int; 2002 Feb; 61(2):525-33. PubMed ID: 11849392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simplified method of producing biologically active monomeric ferritin-insulin for use as a high resolution ultrastructural marker for occupied insulin receptors.
    Smith RM; Jarett L
    J Histochem Cytochem; 1982 Jul; 30(7):650-6. PubMed ID: 7050238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parallel synthesis of indolylquinones and their cell-based insulin mimicry.
    Pirrung MC; Li Z; Hensley E; Liu Y; Tanksale A; Lin B; Pai A; Webster NJ
    J Comb Chem; 2007; 9(5):844-54. PubMed ID: 17595147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Paper chromatographic determination of amino acids in biologically active insulin ultrafiltrates].
    LASCH F; SCHNEIDER G
    Z Vitam Horm Fermentforsch; 1955 Nov; 7(2-3):81-91. PubMed ID: 13312515
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin dependent and independent actions of dietary protein on in vitro protein synthesis in skeletal muscle of rats.
    Nakano K; Hara H
    J Nutr; 1979 Aug; 109(8):1390-8. PubMed ID: 458493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and activity of insulin. XI. Biologically active synthetic peptides of the insulin sequence B22-25.
    Weitzel G; Eisele K; Guglielmi H; Stock W; Renner R
    Hoppe Seylers Z Physiol Chem; 1971 Dec; 352(12):1735-8. PubMed ID: 5145254
    [No Abstract]   [Full Text] [Related]  

  • 10. Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation.
    Jaffa AA; Miller DH; Bailey GS; Chao J; Margolius HS; Mayfield RK
    J Clin Invest; 1987 Dec; 80(6):1651-9. PubMed ID: 3316279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance immunologically cross-reactive with insulin (SICRI) stimulates cell division.
    Osmak M; Sirotkovic M; Levanat S; Korbelik M; Pavelic K
    Oncology; 1989; 46(1):54-7. PubMed ID: 2644605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purified preparations of the amniotic fluid-derived insulin-like growth factor-binding protein contain multimeric forms that are biologically active.
    Busby WH; Hossenlopp P; Binoux M; Clemmons DR
    Endocrinology; 1989 Aug; 125(2):773-7. PubMed ID: 2473891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combining of synthetic insulin chains into biologically active preparations].
    Zahn H; Brinkhoff O; Meienhofer J; Pfeiffer EF; Ditschuneit H; Gloxhuber C
    Z Naturforsch B; 1965 Jul; 20(7):666-70. PubMed ID: 4379782
    [No Abstract]   [Full Text] [Related]  

  • 14. [The immune response to artificial proteins containing biologically active fragments of human IFN-alpha2 and insulin].
    Bocharova OV; MoshkovskiÄ­ SA; Chertkova RV; Kolesanova EF; Dolgikh DA; Kirpichnikov MP
    Mol Biol (Mosk); 2002; 36(1):84-90. PubMed ID: 11862717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [21-arginine-A] insulin: a biologically active analog.
    Ferderigos N; Cosmatos A; Ferderigos A; Katsoyannis PG
    Int J Pept Protein Res; 1979 Jan; 13(1):43-53. PubMed ID: 422323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Introduction of biologically active fragments of interferon-alpha2 and insulin into the artificial protein albebetin affects immunogenicity of the final construct].
    Bocharova OV; MoshkovskiÄ­ SA; Chertikova RV; Abdullaev ZKh; Kolesanova EF; Dolgikh DA; Kirpichnikov MP
    Vopr Med Khim; 2002; 48(1):94-102. PubMed ID: 12068502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB.
    Zhang Z; Li X; Lv W; Yang Y; Gao H; Yang J; Shen Y; Ning G
    Mol Endocrinol; 2008 Jan; 22(1):186-95. PubMed ID: 17885204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramides inhibit phospholipase D-dependent insulin signaling in liver cells of old rats.
    Babenko NA; Kharchenko VS
    Biochemistry (Mosc); 2012 Feb; 77(2):180-6. PubMed ID: 22348478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures.
    Simonson GD; Groskreutz DJ; Gorman CM; MacDonald MJ
    Hum Gene Ther; 1996 Jan; 7(1):71-8. PubMed ID: 8825870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
    Bouider N; Fhayli W; Ghandour Z; Boyer M; Harrouche K; Florence X; Pirotte B; Lebrun P; Faury G; Khelili S
    Bioorg Med Chem; 2015 Apr; 23(8):1735-46. PubMed ID: 25773016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.